To the best of our knowledge, this constitutes the first study documenting a potentiated anticancer effect of paclitaxel while co-administered with AKT siRNA mediated by dendrimer nanovectors to ovarian cancer both in vitro and in vivo. This evidence concerns the gene AKT1 and ovarian carcinoma.